1. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus in the United States, 1999 through 2002. Ann Intern Med. 2006; 144: 705–714.
2. Liang TJ, Rehermann B, Seeff LB, et al. Pathogenesis, natural history, treatment and prevention of hepatitis C. Ann Intern Med. 2000; 132: 296–305.
3. Alter MJ, Kruszon-Moran D, Nainan OV. The prevalence of hepatitis C virus infection in the United States, 1989–1994. N Engl J Med. 1999; 341: 556–562.
4. Armstrong GL. Injection drug users in the United States, 1979–2002, an aging population. Arch Intern Med. 2007; 167: 166–173.
5. Oh DJ, Park YM, Seo YI, et al. Prevalence of HCV infections and distributions of HCV genotypes among Korean blood donors. Ann Lab Med. 2012; 32: 210–215.
6. Vescio MF, Longo B, Babudieri S, et al. Correlates of hepatitis C virus seropositivity in prison inmates: a meta-analysis. J Epidemiol Community Health. 2008; 62: 305–313.
7. Viitanen P, Vartiainen H, Aarnio J, et al. Hepatitis A, B,C and HIV infections among Finnish female prisoners—young females a risk group. J Infect. 2011; 62: 59–66.
8. Thorpe LE, Ouellet LJ, Levy JR, et al. Hepatitis C virus infection: prevalence, risk factors, and prevention opportunities among young injection drug users in Chicago, 1997–1999. J Infect Dis. 2000; 182: 1588–1594.
9. Evans J, Hahn J, Page-Shafer K, et al. Gender differences in sexual and injection risk behavior among active young injection drug users in San Francisco (the UFO study). J Urban Health. 2003; 80: 137–146.
10. Thorpe LE, Ouellet LJ, Hershow R, et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol. 2002; 155: 645–653.
11. Bennett GA, Velleman RD, Barter G, Bradbury C. Gender differences in sharing injecting equipment by drug users in England. AIDS Care. 2000; 12: 77–87.
12. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat. 2006; 13: 34–41.
13. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009; 461: 798–801.
14. van der Berg CHBS, Grady BPX, Schinkel J, et al. Female sex and IL28B, a synergism for spontaneous viral clearance in hepatitis C virus (HCV) seroconverters from a community-based cohort. PLoS One. 2011; 6: e27555
15. Rao HY, Sun DG, Jiang D, et al. IL28B genetic variants and gender are associated with spontaneous clearance of hepatitis C virus infection. J Viral Hepat. 2012; 19: 173–181.
16. Kenny-Walsh E. Clinical outcomes of hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med. 1999; 340: 1228–1233.
17. Levine RA, Schuyler OS, Ploutz-Snyder R, et al. Assessment of fibrosis progression in untreated Irish women with chronic hepatitis C contracted from immunoglobulin anti-D. Clin. Gastroenterol Hepatol. 2006; 2006: 1271–1277.
18. Sangiovanni A, Prati GM, Fasani P, et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology. 2006; 43: 1303–1310.
19. Sarbah S, Gramlich T, Younoszai A, et al. Risk factors for hepatocellular carcinoma in patients with cirrhosis. Dig Dis Sci. 2004; 49: 850–853.
20. Codes L, Aselah T, Cazals-Hatem D, et al. Liver fibrosis in women with chronic hepatitis C: evidence for the negative role of menopause and steatosis and the potential benefit of hormone replacement therapy. Gut. 2007; 56: 390–395.
21. Xu J-W, Gong J, Chang XM, et al. Effects of estradiol on liver estrogen receptor-α and its mRNA expression in hepatic fibrosis in rates. World J Gastroenterol. 2004; 15: 250–254.
22. Xu JW, Gong J, Chang XM, et al. Estrogen reduces CCL4- induced liver fibrosis in rats. World J Gastroenterol. 2002; 8: 883–887.
23. Liu QH, Li DG, Huang X, et al. Suppressive effects of 17beta-estradiol on hepatic fibrosis in CCl4-induced rat model. World J Gastroenterol. 2004; 10: 1315–1320.
24. Hayashida K, Shoji I, Deng L, et al. 17β-estradiol inhibits the production of infectious particles of hepatitis C virus. Microbiol Immunol. 2010; 54: 684–690.
25. Martino VD, Lebray P, Myers RP, et al. Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure. Hepatology. 2004; 40: 1426–1433.
26. Poynard T, Mathurin P, Chin-Lung L, et al. E. A comparison of fibrosis progression in chronic liver disease. J Hepatol. 2003; 38: 257–265.
27. Bellentani S, Pozzato G, Saccoccio G, et al. Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study. Gut. 1999; 44: 874–880.
28. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009; 49: 1335–1374.
29. Hezode C, Lonjon I, Roudot-Thoraval F, et al. Impact of moderate alcohol consumption on histological activity and fibrosis in patients with chronic hepatitis C and specific influence on steatosis: a prospective study. Aliment Pharmacol Ther. 2003; 17: 1031–1037.
30. Hu K-Q, Kyulo NL, Esrailian E, et al. Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: a retrospective study on a large cohort of patients in the United States. J Hepatol. 2004; 40: 147–154.
31. Ortiz V, Berenguer M, Rayon JM, et al. Contribution of obesity to hepatitis C-related fibrosis progression. Am J Gastroenterol. 2002; 97: 2408–2414.
32. Hu SX, Kyulo NL, Xia VW, et al. Factors associated with hepatic fibrosis in patients with chronic hepatitis C: a retrospective study of a large cohort of U.S. patients. J Clin Gastroenterol. 2009; 43: 758–764.
33. Hickman IJ, Clouston AD, Macdonald GA, et al. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut. 2002; 51: 89–94.
34. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009; 361: 580–593.
35. Fried MW, Shiffman M, Reddy R, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002; 347: 975–982.
36. Hayashi J, Kishihara Y, Ueno K, et al. Age-related response to interferon alfa treatment in women vs men with chronic hepatitis C virus infection. Arch Intern Med. 1998; 158: 177–181.
37. Sezaki H, Suzuki F, Kawamura Y, et al. Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads. Dig Dis Sci. 2009; 54: 1317–1324.
38. Villa E, Karampatou A, Cammà C, et al. Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C. Gastroenterology. 2011; 140: 818–829.
39. Vertex Pharmaceuticals Antiviral Drugs Advisory Committee. Telaprevir 375-mg film-coated tablet for the treatment of genotype 1 chronic hepatitis C. FDA Briefing Document. www.fda.gov/downloads/AdvisoryCommittees/…/UCM252562.pdf
. Published April 28, 2011. Accessed November 13, 2012.
41. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for the retreatment of HCV infection. N Engl J Med. 2011; 364: 2417–2428.
42. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011; 364: 1207–1217.
43. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011; 364: 2405–2416.
44. Latt NC, Spencer JD, Beeby PJ, et al. Hepatitis C in injecting drug-using women during and after pregnancy. J Gastroenterol Hepatol. 2000; 15: 175–181.
45. Reddick KLB, Jhaveri R, Gandhi M, et al. Pregnancy outcomes associated with viral hepatitis. J Viral Hepat. 2011; 18: e394–e398.
46. Pergam SA, Wang CC, Gardella CM, et al. Pregnancy complications associated with hepatitis C: data from a 2003–2005 Washington state birth cohort. Am J Obstet Gynecol. 2008; 199: e1–e9.
47. Gervais A, Bacq Y, Bernuau J, et al. Decrease in serum ALT and increase in serum HCV RNA during pregnancy in women with chronic hepatitis C. J Hepatol. 2000; 32: 293–299.
48. Ohto H, Terazawa S, Sasaki N, et al. Transmission of hepatitis C virus from mothers to infants. N Engl J Med. 1994; 330: 744–750.
49. Resti M, Azzari C, Mannelli F, et al. Mother to child transmission of hepatitis C virus: prospective study of risk factors and timing of infection in children born to women seronegative for HIV-1. BMJ. 1998; 317: 437–441.
50. Mast EE, Hwang L-Y, Seto DSY, et al. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J Infect Dis. 2005; 192: 1880–1889.
51. Dal Molin G, D’Agaro P, Ansaldi F, et al. Mother-to-infant transmission of hepatitis C virus: rate of infection and assessment of viral load and IgM anti-HCV as risk factors. J Med Virol. 2002; 67: 137–142.
52. Airoldi J, Berghella V. Hepatitis C and pregnancy. Obstet Gynecol Surv. 2006; 61: 666–672.
53. Murakami J, Nagata I, Iitsuka T, et al. Risk factors for mother-to-child transmission of hepatitis C virus: maternal high viral load and fetal exposure in the birth canal. Hepatol Res. 2012; 648–657.
54. Ogasawara S, Kage M, Kosai K-I, et al. Hepatitis C virus rNA in saliva and breastmilk of hepatitis C carrier mothers. Lancet. 1993; 341: 561
55. Lin H-H, Kao J-H, Hsu H-Y, et al. Absence of infection in breast-fed infants born to hepatitis C virus-infected mothers. J Pediatr. 1995; 126: 589–591.
56. American Academy of Pediatrics Committee on Infectious Diseases. Hepatitis C virus infection. Pediatrics. 1998; 101: 481–485.
57. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2010. MMWR Morb Mortal Wkly Rep. 2010; 59:(No. RR-12): 87
58. Copegus [package insert]. Nutley, NJ: Roche Laboratories; 2011; .
59. Loustaud-Ratti V, Rousseau A, Marquet P, et al. Ribavirin in chronic hepatitis C: past and future. Expert Rev Anti Infect Ther. 2009; 7: 249–253.
60. Yazdani Brojeni P, Matok I, Garcia Bournissen F, et al. A systematic review of the fetal safety of interferon alpha. Reprod Toxicol. 2012; 33: 265–268.
61. Ozaslan E, Yilmaz R, Simsek H, et al. Interferon therapy for acute hepatitis C during pregnancy. Ann Pharmacother. 2002; 36: 1715–1718.
62. Incivek [package insert]. Cambridge, MA: Vertex Pharmaceuticals; 2011; .
63. Victrelis [package insert]. Whitehouse Station, NJ: Merck & Co; 2011; .
64. Ghany MG, Nelson DR, Strader DB, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011; 54: 1433–1444.